1 min read
Add as a preferred source on GoogleDr. Reddy’s Wins Tentative FDA Approval for Yeztugo Generic
The generic targets Gilead Sciences’ twice-yearly HIV prevention medicine.
Dr. Reddy’s Laboratories said Monday that the U.S. Food and Drug Administration tentatively approved its generic targeting Yeztugo, Gilead Sciences’ twice-yearly HIV prevention medicine.
Yeztugo is used for HIV prevention twice a year. The FDA action described by Dr. Reddy’s was tentative.
Riza Dagoc
Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.